StockWatch
·
HomeLiveReports

INDO BORAX & CHEMICALS LTD.-$ Q1 FY27 Results

INDOBORAXQ1 FY27 Results
Filing
Result:Good· Market: Surged#Broad based#Margin expansion

Outlook: Optimistic · Guidance: Cut

MetricValue (₹ Cr)Q4 FY26Q1 FY26
Revenue70.3611.7%31.3%
Total Income72.918.0%28.9%
Expenditure50.910.1%20.6%
PBT22.0026.1%53.1%
Net Profit16.2511.8%59.3%
OPM28.14%6.52pp5.35pp
NPM22.29%0.77pp4.26pp
EPS5.0711.9%59.4%
View full financials

Revenue +31.3% and PAT +59.3% YoY on a clean base with genuine margin expansion (NPM 22.3% vs 18.0%) driven by material cost discipline rather than one-offs, a standout for the chemicals sector and tracking ahead of management's own 20-35% growth guidance.

INDO BORAX · Q1 FY-2027 · THE VERDICT

Strong Q1 execution masks FY27 slowdown; Kronox capex upside deferred

Record profit growth (59% YoY) and pricing power are real, but FY27 guidance slashed to 16–21% growth from prior 20–35%. The call reveals the gap: Q1 benefited from post-acquisition optimization; Q2–Q4 expected softer as EBITDA margin normalizes from 28% to 20%.

08 Sept 2026 · 6 min read

On the headline, Indo Borax delivered a strong quarter: revenue ₹70.4 Cr (+31.3% YoY), PAT ₹16.3 Cr (+59.3% YoY), EBITDA margin 28.1%. But here's the gap that defines the quarter: management downgraded FY27 revenue guidance to ₹250–260 Cr (16–21% growth) from prior guidance of 20–35%, and signalled EBITDA margin compressing from Q1's 28.1% to 20% for the full year. That's an 800 basis-point drop in just three quarters. The call explains why — and where the real franchise strength sits.

Q1 Revenue

₹70.4 Cr

+31.3% YoY

Q1 EBITDA margin

28.1%

vs 20% FY27 guidance

Q1 PAT growth

+59.3%

YoY

Where the growth came from

The 31% revenue growth rests on two legs. First, pricing: boric acid prices moved from ₹127 to ₹155–160 per tonne post-war, and that cost pass-through is holding — customer contracts already locked in at the new levels. Second, capacity: post-Kronox integration (closed Aug 2026), management optimized production scheduling, cutting maintenance downtime and lifting boric acid utilization to 96–98% of nameplate (18,000 of 20,000 tonnes). Both are real. But the 28.1% EBITDA margin is a high-water mark, not sustainable — Q1 was pristine execution, a transitional quarter where everything went right.

What management claimed vs. what holds up

Management's core claims validated against delivered results

Q1 revenue ₹70.4 Cr, +31.3% YoY growth

Delivered ₹70.4 Cr, +31.3% YoY

Supported

EBITDA ₹19.8 Cr, 28.1% margin

OPM confirmed at 28.1%

Supported

PAT ₹16.3 Cr, +59.3% YoY growth

Delivered ₹16.3 Cr, +59.3% YoY

Supported

FY27 guidance ₹250–260 Cr (16–21% growth)

Below prior 20–35% guidance; implies Q2–Q4 slowdown from Q1's 31%

Downgrade, corroborated

Kronox potential 3–3.5x revenue post-capex

Forward-looking; capex phased 2–3 years, benefits FY29–31

Unverified

What changed on this call

  • Kronox acquisition closed (Aug 2026): ₹250 Cr for 64.26% equity; adds 185 products, pharma/lab chemicals, global presence (Europe, N.America)

  • FY27 guidance downgraded: 16–21% growth (₹250–260 Cr) vs prior 20–35%; EBITDA margin guidance 20% implies 800 bps compression from Q1

  • DOT (disodium octaborate tetrahydrate) scaling: targeting 1,500 tonnes FY27 (vs 900 FY26); now 9% of revenue with higher margin profile than commodity boric acid

  • New management team bedded down post-Jan 2026 ownership transition; operational efficiency and commercial execution visibly improved

The bull-bear ledger

Both sides of the case

  • Q1 execution solid: 31% revenue, 59% PAT, 28% EBITDA margin — pricing power evident, capacity optimized post-acquisition

  • Market leader: 50% share of India's ~40,000-tonne boric acid market; only domestic IP-grade producer (FDA/BIS certified)

  • Kronox adds structural capex upside: 3x revenue potential post-Dahej, ₹110 Cr capex over 2–3 years, global pharma/lab distribution, FY29–31 benefit window

  • Product mix diversifying: DOT, IP-grade pharma channels gaining traction; reduces dependence on cyclical steel/refractory (55–60% of current revenue)

  • FY27 guidance downgraded (16–21% from 20–35%): signals caution on macro/seasonality; near-term slowdown, not a miss but a reset

  • Margin compression expected: 800 bps from Q1's 28.1% to FY27's 20% implies Q2–Q4 pressure; Q2 monsoon historically soft

  • Kronox integration unproven: capex timeline 18–24 months; benefits delayed to FY29–31; new leadership team to be proven; 185-product portfolio integration complex

  • Cyclical exposure: 55–60% of boric acid revenue from steel/refractory; if India steel demand slows, volume and pricing both at risk

  • Raw material inflation unresolved: boron ore, sulphuric acid volatile due to war; cost pass-through held 100% so far, but limits exist

  • Capex execution risk: ₹50 Cr Kronox capex over 2–3 years; environmental clearances, construction, equipment sourcing all pose delay risk

How the street is positioned

The stock is overbought. RSI sits at 70.5, and the price has run 138.5% off its 52-week low of ₹211.3; it now trades -7.11% from its all-time high of ₹542.55. The post-result price action tells the story: the day-1 pop of +0.91% faded to +2.05% by day 3, then reversed to -1.75% by day 5. The market's own verdict is caution — enthusiasm about the print didn't hold. On the tape: FII ownership collapsed from 0.45% to 0.13% (down 32 basis points), DII from 2.19% to 0.04% (down 215 basis points). But promoter ownership jumped +7.61 percentage points to 38.41%, signalling inside conviction. The bulk deals over the last six months show no red flags — trading among financial entities, no insider-linked selling near the highs. The overbought RSI plus fading price action plus institution trimming suggest near-term pullback risk. Insiders buying into weakness is credible, but wait for Q2 results before adding.

Risks, ranked by how much they should concern a holder

Risks to monitor, ordered by severity and impact on investment thesis

Margin compression (Q1 28.1% → FY27 20% guidance)

High

800 bps normalization in 9 months implies Q2–Q4 EBITDA pressure. If war-cost pass-through slips or demand softens faster, margin guide at risk. This is the pivot point for full-year credibility.

Kronox integration (capex timeline, synergy realization)

High

Capex 18–24 months to Dahej expansion; full benefits delayed to FY29–31 (2–3 years). If milestones slip, revenue/EBITDA benefit pushed beyond current guidance window. New leadership team unproven.

Cyclical steel/refractory exposure (55–60% of revenue)

Medium

Boric acid demand tied to India steel and refractory demand; both cyclical. Market growing 8% CAGR, but macro downturn could pressure volume and pricing. Requires product mix diversification to de-risk.

Raw material inflation (boron ore, sulphuric acid)

Medium

War-driven volatility continues. Company passed through 100% of cost this quarter (₹127→₹155–160), but limits to pass-through exist. If war ends, deflation risk; if war persists, cost may outpace pass-through.

Capex execution (₹50 Cr Kronox, ₹40–45 Cr organic)

Medium

Environmental clearances, equipment sourcing, construction delays all pose schedule risk. If capex slips, FY29–31 benefit timeline pushed, reducing visibility on structural upside.

Seasonality (Q2 monsoon softness)

Low

Q2 historically lowest-volume quarter; management expects softness. If monsoon is heavier than usual or demand rolls off faster, Q2 miss likely.

What to watch next

Three concrete catalysts that resolve the debate

  • 1 · Q2 FY27 EBITDA margin

    Will the 20% full-year guidance hold? If Q2 comes in above 20%, the margin compression narrative is too pessimistic and the stock re-rates. If below 18%, the full-year guide is at risk and the near-term is messier. This is the litmus test.

  • 2 · Kronox Dahej capex progress

    Site locked, design finalized, customer audits done. Equipment orders, construction start, and timeline adherence are the next milestones. Any delays push FY29–31 benefits and reduce visibility on structural upside.

  • 3 · Boric acid pricing durability

    Can ₹155–160 hold if war-driven cost inflation moderates? Contracts locked now, but renewal risk exists in Q3–Q4. If pricing slips, margin guide crumbles.

  • 4 · DOT ramp and IP-grade pharma adoption

    Targeting 1,500 tonnes FY27. If achieved, margin accretion visible. If ramp slips, full-year mix deteriorates and margin comes in below 20%.

The quarter is steady execution, not a step-change. Q1 was helped by the Kronox close and immediate cost optimization; that 28% EBITDA margin is a high-water mark. The call made clear that Q2 monsoon will soften both volume and realization, dragging the full-year margin guidance to 20% — a reset, candid but realistic.

The Kronox capex is the structural story (3x revenue potential, FY29–31), but it's 18–24 months away. Near-term, the franchise lives or dies on whether it holds the 20% EBITDA margin in Q2–Q4 and whether raw material cost pass-through sticks. The stock is overbought (RSI 70.5); post-result enthusiasm faded by day 5. Promoter buying is credible, but institutions are trimming (FII −32 bps, DII −215 bps). Wait for Q2 results.

The number to track from here: FY27 EBITDA margin. If Q2 comes in above 20%, the margin compression narrative is too pessimistic. If below 18%, the full-year guide is in doubt and the near-term is messier than expected.

Informational and educational content only. Not investment advice.